JP2001513629A5 - - Google Patents

Download PDF

Info

Publication number
JP2001513629A5
JP2001513629A5 JP1998536415A JP53641598A JP2001513629A5 JP 2001513629 A5 JP2001513629 A5 JP 2001513629A5 JP 1998536415 A JP1998536415 A JP 1998536415A JP 53641598 A JP53641598 A JP 53641598A JP 2001513629 A5 JP2001513629 A5 JP 2001513629A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998536415A
Other languages
English (en)
Other versions
JP2001513629A (ja
JP4191255B2 (ja
Filing date
Publication date
Priority claimed from GBGB9703592.7A external-priority patent/GB9703592D0/en
Priority claimed from GBGB9800113.4A external-priority patent/GB9800113D0/en
Application filed filed Critical
Priority claimed from PCT/GB1998/000569 external-priority patent/WO1998037217A1/en
Publication of JP2001513629A publication Critical patent/JP2001513629A/ja
Publication of JP2001513629A5 publication Critical patent/JP2001513629A5/ja
Application granted granted Critical
Publication of JP4191255B2 publication Critical patent/JP4191255B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

Figure 2001513629
Figure 2001513629
Figure 2001513629
JP53641598A 1997-02-21 1998-02-23 ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質 Expired - Fee Related JP4191255B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9703592.7 1997-02-21
GBGB9703592.7A GB9703592D0 (en) 1997-02-21 1997-02-21 Poxvirus chemokine-binding protein
GB9800113.4 1998-01-05
GBGB9800113.4A GB9800113D0 (en) 1998-01-05 1998-01-05 A soluble vaccinia virus protein that binds chemokines
PCT/GB1998/000569 WO1998037217A1 (en) 1997-02-21 1998-02-23 A soluble vaccinia virus protein that binds chemokines

Publications (3)

Publication Number Publication Date
JP2001513629A JP2001513629A (ja) 2001-09-04
JP2001513629A5 true JP2001513629A5 (ja) 2004-12-09
JP4191255B2 JP4191255B2 (ja) 2008-12-03

Family

ID=26311039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53641598A Expired - Fee Related JP4191255B2 (ja) 1997-02-21 1998-02-23 ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質

Country Status (7)

Country Link
US (3) US6355252B1 (ja)
EP (2) EP1405916A1 (ja)
JP (1) JP4191255B2 (ja)
AT (1) ATE323170T1 (ja)
AU (1) AU749921B2 (ja)
DE (1) DE69834179T2 (ja)
WO (1) WO1998037217A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405916A1 (en) * 1997-02-21 2004-04-07 Isis Innovation Limited Recombinant vaccinia virus incapable of expressing the A41L gene
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO2002080948A1 (en) * 2001-04-05 2002-10-17 The Trustees Of Princeton University Compositions and methods for treating inflammation and related conditions
WO2003005953A2 (en) * 2001-07-12 2003-01-23 Immunex Corporation Viral proteins capable of binding lar
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
CA2460321A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Chemokines as adjuvants of immune response
WO2004005892A2 (en) * 2002-07-10 2004-01-15 The Regents Of The University Of California Antimicrobial activity of interferon-inducible elr chemokines
EP2269618A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
WO2005017208A1 (en) * 2003-07-31 2005-02-24 George Mason Intellectual Properties, Inc. Compositions and methods for treating or preventing hiv infection
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US20070160571A1 (en) * 2006-01-11 2007-07-12 Mitchell Krathwohl Composition and method for inducing protective vaccine response
WO2006076383A2 (en) * 2005-01-11 2006-07-20 Rosetta Stone Labs, Llc Composition and method for inducing a protective vaccine response
KR20090004839A (ko) * 2005-09-07 2009-01-12 제네렉스, 인코포레이티드 Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US20070134234A1 (en) * 2005-09-29 2007-06-14 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
ATE485517T1 (de) 2006-03-22 2010-11-15 Viral Logic Systems Technology Verfahren zur identifizierung von polypeptid- targets
WO2008096359A2 (en) * 2007-02-08 2008-08-14 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US8263064B2 (en) 2007-06-04 2012-09-11 Rappaport Family Institute For Research In The Medical Sciences Method of suppressing disease severity of multiple sclerosis using chemokine CXC11
WO2009082594A2 (en) 2007-11-26 2009-07-02 Fox Chase Cancer Center Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
BR112012005774B8 (pt) 2009-09-14 2023-02-14 Jennerex Inc uso de um inibidor de quinase antiangiogênico no tratamento de câncer
CN103429258B (zh) 2011-01-04 2016-03-09 新罗杰公司 通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU718049B2 (en) * 1995-04-19 2000-04-06 Viron Therapeutics, Inc. Chemokine binding protein and methods of use therefor
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
EP1405916A1 (en) * 1997-02-21 2004-04-07 Isis Innovation Limited Recombinant vaccinia virus incapable of expressing the A41L gene
WO1998036766A1 (en) * 1997-02-21 1998-08-27 Isis Innovation Limited Anti-hiv protein
JP2001168323A (ja) * 1999-12-06 2001-06-22 Mitsubishi Electric Corp 半導体装置の製造方法

Similar Documents

Publication Publication Date Title
JP2001522291A5 (ja)
JP2000509635A5 (ja)
JP2001514772A5 (ja)
JP2000510751A5 (ja)
JP2000509942A5 (ja)
JP2000509637A5 (ja)
JP2002508784A5 (ja)
JP2001500448A5 (ja)
JP2002513449A5 (ja)
JP2000509587A5 (ja)
JP2000507369A5 (ja)
JP2000510793A5 (ja)
JP2000508866A5 (ja)
JP2001510406A5 (ja)
JP2000508841A5 (ja)
JP2000508680A5 (ja)
JP2001520617A5 (ja)
JP2000509804A5 (ja)
JP2000509853A5 (ja)
JP2000510969A5 (ja)
JP2000509755A5 (ja)
JP2001513629A5 (ja)
JP2000508836A5 (ja)
JP2000510247A5 (ja)
JP2000509520A5 (ja)